Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Clin. Diabetes Healthc.

Sec. Diabetes and Pregnancy

Volume 6 - 2025 | doi: 10.3389/fcdhc.2025.1682012

This article is part of the Research TopicPhysiology and Pathophysiology of PlacentaView all 11 articles

Maternal circulating GPIHBP1 levels and neonatal outcomes in patients with gestational diabetes mellitus: A pilot study

Provisionally accepted
Mayu  WatanabeMayu Watanabe1*Jun  EguchiJun Eguchi2Eriko  EtoEriko Eto3Hisashi  MasuyamaHisashi Masuyama3Jun  WadaJun Wada2
  • 1Department of Diabetology and Endocrinology, NHO Okayama Medical Center, Okayama, Japan
  • 2Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences, okayama, Japan
  • 3Department of Obstetrics and Gynecology, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences, okayama, Japan

The final, formatted version of the article will be published soon.

The prevalence of gestational diabetes mellitus (GDM) is significantly increasing. Hyperglycaemia and dyslipidaemia have been demonstrated to contribute to endothelial dysfunction linked to foetal–placental circulation. Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1) is crucial for the lipolytic processing of TG-rich lipoproteins through the anchoring of lipoprotein lipase (LPL). In this study, circulating GPIHBP1 levels during pregnancy were evaluated, and their associations with hypertriglyceridaemia and the perinatal outcomes of GDM were evaluated. This study included 12 pregnant women with GDM and 21 pregnant women with normal glucose tolerance (NGT). No significant differences in obstetrical outcomes were detected between the two groups. In participants with NGT, circulating GPIHBP1 levels were markedly lower in the 3rd trimester than in the 2nd trimester and at delivery. In women with GDM, circulating GPIHBP1 levels were unchanged during the 3rd trimester, and circulating GPIHBP1 levels throughout the 3rd trimester were negatively correlated with neonatal birth weight percentile and umbilical venous pO2 (ρ=-0.636, p=0.026; ρ=-0.657, p=0.020). Our findings suggest a possible association between circulating GPIHBP1 levels and perinatal outcomes in patients with GDM.

Keywords: glycosylphosphatidylinositol-anchored high-density lipoprotein-bindingprotein 1 (GPIHBP1), Gestational diabetes mellitus (GDM), Perinatal outcomes, Placenta, Triglyceride (TG)

Received: 08 Aug 2025; Accepted: 25 Sep 2025.

Copyright: © 2025 Watanabe, Eguchi, Eto, Masuyama and Wada. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Mayu Watanabe, mayuw294@gmail.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.